Categories AlphaGraphs, Earnings, Health Care
ANGO Earnings: A snapshot of AngioDynamics’ Q2 2024 results
AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a net loss, on an adjusted basis, for the second quarter of 2024 when its revenue declined. The medical device maker also provided guidance for fiscal 2024.
Net loss, excluding special items, was $0.05 per share in the November quarter, compared to earnings of $0.01 per share in the same period of 2023. On an unadjusted basis, net loss was $29.05 million or $0.72 per share in Q2, compared to a loss of $8.49 million or $0.21 per share in the prior-year quarter.
Second-quarter revenues decreased 7% year-over-year to $79.1 million. The company expects fiscal 2024 revenues to be in the range of $320 million to $325 million.
Commenting on the results, AngioDynamics’ CEO Jim Clemmer said, “Currently, more than 80% of our Med Tech revenue utilizes third-party manufacturing. Fully shifting both Med Device and Med Tech to this model will allow us to more effectively compete in our chosen markets, fundamentally changing our corporate gross margin profile and driving us to profitability in two years.”
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
